Oncology

Research

  1. Gibbon VE, Strkalj G, Paximadis M, Ruff P and Penny CB.
    The sex profile of skeletal remains from a cemetery of Chinese indentured labourers in South Africa. South African Journal of Science 2010; 106(7/8) (Art #191): 65-68.
  2. . Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner K, Wolf M and Gansert J. Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2010; 28(31): 4697-4705.
  3. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci-Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson-Ansah A, Legros L, Harousseau JL, Rigal-Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pane F, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde-Dahl T, Hjorth-Hansen H, Jedrzejczak W, Dmoszynska A, Starzak-Dwozdz J, Holowiecki J, Kyrcz-Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez-López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al-Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent DJ. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; Jun 17; 362(24): 2251-9.
  4. Vorobiof DA and Ruff P. Cancer in South Africa and the Role of the National Cancer Registry. The ASCO Post 2011; 2(7).
  5. Louw V, Dreost L, Ruff P, Jogessar V, Moodley D, Novitzky N and Willem P. Guideline: Recommendations for the management of adult chronic myeloid leukaemia in South Africa. South African Medical Journal 2011; 101(11): 840-846.
  6. Louw V, Bassa F, Chan SW, Dreosti L, du Toit M, Ferreira M, Gartrell F, Gunther K, Jogessar V, Littleton N, Mahlangu J, McDonald A, Patel M, Pool R, Ruff P, Schmidt A, Sissolak G, Swart A, Verburgh E and Webb M. Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. South African Medical Journal 2011; 101(12): 900-906.
  7. Abratt RP, Dreosti L and Ruff P. Cancer care in South Africa. Lancet Oncology 2012; 13(8): 324.
  8. van Cutsem E, Tabernero J, Lakomi R, Prenen H, Prausona J, Macarulla T, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J and Allegra C. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR). Journal of Clinical Oncology 2012; 30: 3499-3506.
  9. Penny CB, Milner, BL, Gibbon VE, Ruff P. The HT29 and DLD-1 colon cancer cell lines contain cancer stem cells. Clinical Anatomy 2013. Published online: 3 Apr 2013. DOI: 10.1002/ca.22235
  10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment in wild- type RAS metastatic colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
  11. Tabernero J, van Cutsem E, Lakomi R, Prausona J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J, Soussan-Lazard K, Chevalier S and Allegra C. Aflibercept versus placebo in combination with FOLFIRI in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR Trial. European Journal of Cancer 2014; 50: 320-331.
  12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner KS, Wolf M and Gansert J. Final results from PRIME: Randomized phase 3 study of panitumumab (pmab) with FOLFOX4 for 1st line metastatic colorectal cancer (mCRC). Annals of Oncology 2014; 25: 1346–1355.
  13. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S and Sidhu R. Panitumumab Versus Cetuximab in Patients With Metastatic Colorectal Cancer. Lancet Oncology 2014; 15(7): 569-579.
  14. Price TJ, Peeters M, Ruff P, Murugappan S and Sidhu R. ASPECCT: panitumumab versus cetuximab for colorectal cancer ? Authors' reply. Lancet Oncology 2014; 15: e303.
  15. Singh E, Sengayi M, Urban M, Babb C, Kellett P and Ruff P. The South African National Cancer Registry: an update. Lancet Oncology 2014; 15: e363.
  16. Ruff P , Ferry DR, Lakomy R, Prausova J, van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll H, Moisyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Tabernero J and van Cutsem E. Long term efficacy and safety of aflibercept in combination with FOLFIRI in patients with mCRC who progressed on previous oxaliplatin-based therapy. European Journal of Oncology 2014; epub Nov 11.
  17. Logan TF, Szczylik C, Tannir N, Benedetto P, Makhson A, McDermott D, Ruff P, Mikulás J, Dutcher JP, Berkenblit A, Galand L, Krygowski M and Hudes G. Effect of Nephrectomy Status on Temsirolimus Efficacy in Patients with Advanced Poor-Prognostic Renal Cell Cancer. Medical Oncology 2014; (submitted).
  18. van Cutsem E, Joulain F, Hoff P, Mitchell E, Ruff P, Lakomy R, Prausova J, Moiseyenko V, Van Hazel G, Cunningham D, Arnold D, Schmoll H, ten Tije A, McKendrick J, Kroening H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath R, Macarulla T, Allegra C, Tabernero J. Aflibercept/FOLFIRI vs Placebo/FOLFIRI in second line Metastatic Colorectal Cancer: A post Hoc Analysis of Survival in the phase III VELOUR study Subsequent to Exclusion of Patients Who Had Recurrence During or Within 6 Months of Completing only Adjuvant Oxaliplatin-Based Therapy. Targeted Oncology 2014 (submitted).
  19. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, Kellett P and Underwood M. Establishment of a cancer surveillance program in a developing country: South African Experience. Lancet Oncology 2015 (submitted)